이 페이지는 자동 번역되었으며 번역의 정확성을 보장하지 않습니다. 참조하십시오 영문판 원본 텍스트의 경우.

MSC-DNX-2401의 재발성 고등급 신경아교종 환자 치료

2026년 9월 23일 업데이트: M.D. Anderson Cancer Center

종양 선택적 종양 용해성 아데노바이러스 DNX-2401이 로드된 동종 골수 인간 중간엽 줄기 세포의 1상 임상 시험

This phase I trial studies best dose and side effects of oncolytic adenovirus DNX-2401 in treating patients with high-grade glioma that has come back (recurrent). Oncolytic adenovirus DNX-2401 is made from the common cold virus that has been changed in the laboratory to make it less likely to cause an infection (such as a cold). The virus is also changed to target brain cancer cells and attack them.

연구 개요

상세 설명

PRIMARY OBJECTIVES:

I. To determine the maximal tolerated dose (MTD) of allogeneic bone marrow-derived human mesenchymal stem cells (BM-hMSCs) loaded with the oncolytic adenovirus DNX-2401 (BM-hMSCs-DNX2401) administered by intra-arterial injection (i.e., transfemoral endovascular intracranial injection) in patients with recurrent glioblastoma (GBM), IDH-mutant astrocytoma grade 4, gliosarcoma, or wild-type IDH-1 anaplastic astrocytoma.

II. To determine the local and systemic toxicity of allogeneic BM-hMSCs-DNX2401 administered by intra-arterial injection (i.e., transfemoral endovascular intracranial injection) in patients with recurrent GBM, gliosarcoma or wild-type IDH-1 anaplastic astrocytoma.

III. To determine at the molecular and cellular level the capacity of allogeneic BM-hMSCs-DNX2401 administered intra-arterially to home to and deliver DNX-2401 to recurrent GBM, gliosarcoma or wild-type IDH-1 anaplastic astrocytoma by analyzing post-treatment surgical brain tumor specimens for the expression and distribution of adenoviral proteins.

SECONDARY OBJECTIVES:

I. To assess shedding of adenovirus into the blood, sputum, and nasopharynx after intra-arterial administration of BM-hMSCs-DNX2401 in patients with recurrent GBM, gliosarcoma or wild-type IDH-1 anaplastic astrocytoma.

II. To assess the development of anti-adenovirus antibodies after intra-arterial administration of BM-hMSCs-DNX2401 in patients with recurrent GBM, gliosarcoma or wild-type IDH-1 anaplastic astrocytoma.

III. To evaluate immune-mediated cytokine responses after intra-arterial administration of BM-hMSCs-DNX2401 in patients with recurrent GBM, gliosarcoma or wild-type IDH-1 anaplastic astrocytoma.

IV. To assess anti-tumoral activity and to determine progression-free survival (PFS) and overall survival (OS) after intra-arterial administration of BM-hMSCs-DNX2401 in patients with recurrent GBM, gliosarcoma or wild-type IDH-1 anaplastic astrocytoma.

OUTLINE: This is a dose-escalation study.

PART I: Patients receive one or two infusions of BM-hMSCs-DNX-2401 intra-arterially (IA) over 20-30 minutes on day 0. Dose level 1-5 will receive 1 infusion. Dose level 6 will receive 2 infusions.

PART II: Patients receive one or two infusions BM-hMSCs-DNX-2401 IA, depending on the highest dose that was tolerated in Part 1. After 2 weeks, patients undergo surgery where the tumor is removed, then receive intramural injection of BM-hMSCs-DNX-2401 into the resection cavity.

After completion of study treatment, patients in both part I and II are followed up on days 1, 4, 7, and 14 of month 1,every 6 weeks for 6 months (4 visits), then every 8 weeks for 1 year (6 visits), then every 4 months for 1 year (3 visits), then every 6 months until the tumor grows back. Patients treated at Dose level 6 in Part 1 and Part 2 are also followed up on Day 12, then on Day 1, 4, and 7 after second infusion, then on Day 1, 7, and 14 post-craniotomy for Part 2, Dose Level 6, then ,every 6 weeks for 6 months (4 visits), then every 8 weeks for 1 year (6 visits), then every 4 months for 1 year (3 visits), then every 6 months until the tumor grows back.

연구 유형

중재적

등록 (추정된)

36

단계

  • 1단계

연락처 및 위치

이 섹션에서는 연구를 수행하는 사람들의 연락처 정보와 이 연구가 수행되는 장소에 대한 정보를 제공합니다.

연구 연락처

연구 장소

    • Texas
      • Houston, Texas, 미국, 77030
        • 모병
        • M D Anderson Cancer Center
        • 연락하다:
          • Frederick F. Lang
          • 전화번호: 713-792-2400
        • 수석 연구원:
          • Frederick F. Lang

참여기준

연구원은 적격성 기준이라는 특정 설명에 맞는 사람을 찾습니다. 이러한 기준의 몇 가지 예는 개인의 일반적인 건강 상태 또는 이전 치료입니다.

자격 기준

공부할 수 있는 나이

18년 이상 (성인, 고령자)

건강한 자원 봉사자를 받아들입니다

아니

연구 대상 성별

모두

설명

Inclusion Criteria:

Subjects must meet the following inclusion criteria to be eligible and enroll:

  1. Subjects must be willing and able to provide informed consent, undergo and comply with all study assessments, and adhere to the protocol schedule.

  2. Patients with recurrent malignant GBM or gliosarcoma will be eligible. Patients with recurrent anaplastic astrocytoma with wild-type IDH-1 gene will also be eligible if there is a significant enhancing mass on MRI (≥1.0 cm in diameter with upper limit of 5 cm maximal diameter) because their prognosis/behavior is similar to GBM. Subjects with an initial diagnosis of an IDH-mutant grade 2 or 3 astrocytoma are also eligible at recurrence if a biopsy at recurrence is determined to be IDH-mutant grade 4 astrocytoma, and there is a significant enhancing mass on MRI (≥1.0 cm in diameter with upper limit of 5 cm maximal diameter). A pathology report constitutes adequate documentation of histology for study inclusion.

  3. Patients must show unequivocal evidence for tumor recurrence or progression by MRI scan after failing prior surgical resection, biopsy, chemotherapy or radiation. A baseline MRI must be performed within 24 days prior to registration. Biopsy is encouraged at the time of recurrence if it is unclear that there is recurrent tumor. However, biopsy is not required if the practicing physician thinks that there is adequate radiographic and clinical evidence for recurrence.

  4. Male or female patients ≥ 18 years of age.

  5. Patients must be able to undergo endovascular treatment based on Doppler studies showing ICA that is less than 50% occluded.

  6. For patients undergoing resection for biological endpoints, tumors must be surgically resectable at the time of baseline evaluation and craniotomy for tumor resection is indicated as part of their standard medical care.

  7. Tumors must be ≥1.0 cm in diameter with upper limit of 5 cm maximal diameter.

  8. Patients must have a Karnofsky performance score ≥ 70.

  9. Patients must have a life expectancy of at least 16 weeks.

  10. Patients must have adequate bone marrow function (absolute granulocyte count > 1,500 and platelet count of > 75,000), adequate liver function (SGPT and SGOT and bilirubin < 2 times institutional normal ranges), and adequate renal function (creatinine < 2.0 times institutional normal) prior to starting therapy.

  11. Prothrombin time/international normalized ratio (PT/INR) or partial thromboplastin time (PTT) ≤ 1.5x ULN.

  12. Subjects who have received the following chemotherapies must have completed them within the following time periods prior to Baseline/Day 0 of hMSC-DNX2401 delivery with recovery from any drug-related toxic effects to Grade 1, or less, severity:

    • Four weeks from cytotoxic agents (3 weeks from procarbazine or Temozolomide, 2 weeks from vincristine)
    • 6 weeks from nitrosoureas (CCNU, BCNU)
    • Four weeks from any targeted investigational agent
    • One week from non-cytotoxic agents
  13. This study was designed to include women and minorities, but was not designed to measure differences of intervention effects. Males and females will be recruited with no preference to gender.

  14. No exclusion to this study will be based on race. Minorities will actively be recruited to participate. The malignant glioma patient population treated at MDACC over the past year is as follows:

    • American Indian or Alaskan Native - 0
    • Asian or Pacific Islander - <2%
    • Black, not of Hispanic Origin - 3%
    • Hispanic - 6%
    • White, not of Hispanic Origin - 88%
    • Other or Unknown - 2%
    • Total - 100%
  15. Patients must be 8 weeks from radiotherapy to minimize the potential for MRI changes related to radiation necrosis that might be misdiagnosed as progression of disease, or 4 weeks if a new lesion, relative to the pre-radiation MRI, develops that is outside the primary radiation field (beyond 80% isodose line). However, if a biopsy is undertaken prior to these times and this biopsy documents histological evidence for recurrent disease, then patients will be eligible regardless of the time after radiation.

  16. Patients must be willing to forego other cytotoxic and non-cytotoxic drug or radiation therapy against the tumor while enrolled in the study.

  17. Women of childbearing potential must have a negative urine or serum pregnancy test at screening.

  18. Subjects and their partners must be willing to use effective birth control during the study and for up to 6 months following administration of hMSC-DNX2401. Birth control that is acceptable to use in this study:

    • Using twice the normal protection of birth control (i.e., double-barrier) by using a condom AND spermicidal jelly or foam, or a diaphragm AND spermicidal jelly or foam. A spermicidal jelly or foam must be used in addition to a barrier method (e.g., condom or diaphragm)
    • Birth control pills ("The Pill")
    • Depot or injectable birth control
    • IUD (Intrauterine Device)
    • Birth Control Patch (e.g., Othro Evra®)
    • NuvaRing®
    • Surgical sterilization (i.e., tubal ligation or hysterectomy for women or vasectomy for men)

Exclusion Criteria:

  1. Histology other than GBM, gliosarcoma, IDH wild-type astrocytoma grade III or IDH-mutant astrocytoma grade 4.
  2. Tumor foci detected below the tentorium or beyond the cranial vault.
  3. Tumor within the posterior fossa.
  4. Tumor with leptomeningeal spread.
  5. Difficulty in obtaining vascular access for percutaneous procedure.
  6. Ipsilateral carotid stenosis (>50%, by Doppler studies).
  7. Thrombophilias or primary hematological diseases.
  8. Transfusions or medications (G-CSF) to treat pancytopenia or other hematological conditions < 28 days prior to Baseline/Day 0/hMSC-DNX2401 administration.
  9. Biologic/immunotherapy within 2 weeks of baseline.
  10. Clinical or laboratory evidence of inflammatory and/or autoimmune disorders.
  11. Any contraindication for undergoing MRI such as: individuals with pacemakers, epicardial pacer wires, infusion pumps, surgical and/or aneurysm clips, shrapnel, metal prosthesis, implants with potential magnetic properties, metallic bodies in the eyes, etc. In addition, subjects must present with tumor that is evaluable by MRI.
  12. Pregnant or nursing females.
  13. Evidence of active uncontrolled infection or unstable or severe intercurrent medical conditions. All subjects must be afebrile (i.e., <38.0° Celsius [C]).
  14. Any medical condition that precludes surgery or endovascular treatment
  15. Alcoholism (dependency), alcohol or substance abuse within twelve (12) months prior to screening that has caused health consequences.
  16. Immunocompromised subjects or those with autoimmune conditions, active hepatitis (Liver function tests > 2x normal) or human immunodeficiency virus (HIV) seropositivity.
  17. Evidence of bleeding diathesis or use of anticoagulant medication or any medication that may increase the risk of bleeding that cannot be stopped prior to surgery. If the medication can be discontinued prior to DNX-2401 injection then the subject may be eligible following consultation with the Study Chair. Low weight heparin and Lovenox (enoxaparin) administered on a temporary limited basis for post procedure DVT prophylaxis is permitted.
  18. History or current diagnosis of any medical or psychological condition that in the Investigator's opinion might interfere with the subject's ability to participate or inability to obtain informed consent because of psychiatric or complicating medical problems.
  19. Encephalitis, multiple sclerosis or other central nervous system (CNS) infection or primary CNS disease that would interfere with subject evaluation.
  20. Subjects with known Li-Fraumini Syndrome or with a known germ line deficit in the retinoblastoma gene or its related pathways.
  21. Subjects with significant systemic or major illnesses including but not limited to: congestive heart failure, ischemic heart disease, cerebrovascular disease (history of strokes or TIAs in large vessel or small vessel distribution), kidney disease or renal failure, active liver disease, organ transplantation, or significant psychiatric disorder.
  22. Enrollment in a concomitant therapeutic clinical study.
  23. Any condition that prevents compliance with the protocol or adherence to therapy.
  24. For patients enrolled in the biological endpoint phase of the study, patients will be excluded if in the assessment of the surgeon, after resecting the tumor, there is high likelihood of injecting BM-hMSC-DNX2401 into the ventricles.

공부 계획

이 섹션에서는 연구 설계 방법과 연구가 측정하는 내용을 포함하여 연구 계획에 대한 세부 정보를 제공합니다.

연구는 어떻게 설계됩니까?

디자인 세부사항

  • 주 목적: 치료
  • 할당: 무작위화되지 않음
  • 중재 모델: 순차적 할당
  • 마스킹: 없음(오픈 라벨)

무기와 개입

참가자 그룹 / 팔
개입 / 치료
실험적: Part I (oncolytic adenovirus Ad5-DNX-2401)

Patients receive oncolytic adenovirus Ad5-DNX-2401 IA over 20-30 minutes on day 0.

Given IA

다른 이름들:
  • Ad5-Delta24RGD
  • DNX-2401
  • DNX2401
  • 종양 용해성 Ad5-Delta 24RGD
  • 종양 용해성 아데노바이러스 Ad5-Delta 24RGD
실험적: Part II (oncolytic adenovirus Ad5-DNX-2401, surgery)

Patients receive oncolytic adenovirus Ad5-DNX-2401 as in part I. After 2 weeks, patients undergo surgery, then receive oncolytic adenovirus Ad5-DNX-2401 IA over 20-30 minutes.

Undergo surgery

Given IA

다른 이름들:
  • Ad5-Delta24RGD
  • DNX-2401
  • DNX2401
  • 종양 용해성 Ad5-Delta 24RGD
  • 종양 용해성 아데노바이러스 Ad5-Delta 24RGD

연구는 무엇을 측정합니까?

주요 결과 측정

결과 측정
측정값 설명
기간
Maximum-tolerated dose (MTD)
기간: Up to 28 days

The MTD will be defined as the dose below the dose that results in greater than or equal to one-third of the subjects exposed who experienced grade 3 or 4 (except hematological, grade 4 required) toxicity according to National Cancer Institute Common Toxicity Criteria that is deemed to be at least "probably related" to the study drug (i.e., dose-limiting toxicity [DLT]).

Up to 28 days
Incidence of adverse events (AEs)
기간: Up to 1 year

AEs will be summarized both overall and by dose group and tabulated by severity, relationship to BM-hMSCs-DNX 2401and causality. The number and percentage of subjects experiencing AEs will be tabulated by body system/preferred term both overall and by dose group. When an AE occurs more than once, the maximum severity and causality will be counted.

Up to 1 year

2차 결과 측정

결과 측정
측정값 설명
기간
진행 시간
기간: 최대 1년
최대 1년
Tumor response
기간: Up to 1 year

Will be based upon change in tumor size by serial magnetic resonance imaging scans post injection.

Up to 1 year
Virus replication in tumor
기간: Up to 1 year

Detection of replicating delta-24-RGD-4C in tumor tissue will be done by immunohistochemistry against E1A protein and hexon protein.

Up to 1 year
Virus shedding
기간: Up to 1 year

Polymerase chain reaction of serum, nasopharyngeal secretions, and urine will be performed.

Up to 1 year
Immunogenicity based on adenoviral (AdV) antibodies
기간: Up to 1 year

Enzyme-linked immunosorbent assay (ELISA) will be used to detect AdV antibodies in serum and virus assays to determine antibody titers (anti-AdV5 antibody immunofluorescence) will be performed.

Up to 1 year

공동 작업자 및 조사자

여기에서 이 연구와 관련된 사람과 조직을 찾을 수 있습니다.

협력자

수사관

  • 수석 연구원: Frederick F Lang, M.D. Anderson Cancer Center

간행물 및 유용한 링크

연구에 대한 정보 입력을 담당하는 사람이 자발적으로 이러한 간행물을 제공합니다. 이것은 연구와 관련된 모든 것에 관한 것일 수 있습니다.

연구 기록 날짜

이 날짜는 ClinicalTrials.gov에 대한 연구 기록 및 요약 결과 제출의 진행 상황을 추적합니다. 연구 기록 및 보고된 결과는 공개 웹사이트에 게시되기 전에 특정 품질 관리 기준을 충족하는지 확인하기 위해 국립 의학 도서관(NLM)에서 검토합니다.

연구 주요 날짜

연구 시작 (실제)

2019년 2월 12일

기본 완료 (추정된)

2027년 9월 30일

연구 완료 (추정된)

2027년 9월 30일

연구 등록 날짜

최초 제출

2019년 3월 28일

QC 기준을 충족하는 최초 제출

2019년 3월 28일

처음 게시됨 (실제)

2019년 4월 1일

연구 기록 업데이트

마지막 업데이트 게시됨 (실제)

2026년 9월 25일

QC 기준을 충족하는 마지막 업데이트 제출

2026년 9월 23일

마지막으로 확인됨

2026년 9월 1일

추가 정보

이 연구와 관련된 용어

기타 연구 ID 번호

  • 2015-0953
  • 2015-0953 (기타 식별자: M D Anderson Cancer Center)
  • NCI-2019-01195 (레지스트리 식별자: CTRP (Clinical Trial Reporting Program))

약물 및 장치 정보, 연구 문서

미국 FDA 규제 의약품 연구

예

미국 FDA 규제 기기 제품 연구

아니

이 정보는 변경 없이 clinicaltrials.gov 웹사이트에서 직접 가져온 것입니다. 귀하의 연구 세부 정보를 변경, 제거 또는 업데이트하도록 요청하는 경우 register@clinicaltrials.gov. 문의하십시오. 변경 사항이 clinicaltrials.gov에 구현되는 즉시 저희 웹사이트에도 자동으로 업데이트됩니다. .

구독하다